Methods and kits for monitoring anticoagulation therapy
By using deficient plasma containing correction factor VII to bind with thromboplastin, the activation of FIX is bypassed, and the effects of FII and FX are accurately monitored. This solves the problems of inaccurate monitoring and high cost in existing technologies, and enables safer and more economical dose adjustment of anticoagulation therapy.
Patent Information
- Application Number
- CN202580018899.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-09-03
- Filing Date
- 2025-01-29
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies for monitoring anticoagulation therapy, especially VKA therapy, are not sensitive enough to coagulation factors FII, FVII, and FX, leading to inaccurate dose adjustments and the risk of thromboembolism or abnormal bleeding. Furthermore, existing methods are costly and involve numerous steps.
A novel alternative reagent is used, which lacks factors II and X but contains factor VII corrected to more than 50%. By mixing it with the plasma to be tested, factor X is activated by thromboplastin without activating factor IX, thus bypassing the activation of FIX and measuring only the effects of FIX and FX.
It enables more accurate monitoring of coagulation factor FII and FX activity, reduces the risk of thromboembolism, reduces the risk of abnormal bleeding, and lowers manufacturing costs.
Smart Images

Figure CN123125340A_ABST
Abstract
Description
[0001] Invention Field This disclosure relates to medical diagnostics and drug monitoring, specifically to the field of measuring blood clotting in patients taking anticoagulant therapy drug compounds. Background Technology
[0002] Blood clotting is a mechanism that prevents continued blood loss when any part of the circulatory system is damaged. Clotting refers to the formation of a semi-solid clump of blood that acts to block a wound in a blood vessel. The circulatory system comprises a series of interacting components in the blood and blood vessel walls, which must be kept in balance. A sluggish system response can lead to a serious, even fatal, risk of bleeding. Conversely, an overactive clotting response can lead to the risk of blood clots forming in the circulatory system (i.e., thromboembolism), blocking arteries and potentially causing fatal consequences due to tissue necrosis (cell death).
[0003] Anticoagulants, or "blood thinners," are among the most commonly used drug classes. Within this class, vitamin K antagonists (VKAs, coumarin derivatives) are a special type of medication that can be administered orally. Due to the delicate balance of the blood clotting system and the variability in patient sensitivity and responsiveness to treatment, VKA dosages should be adjusted with caution and monitored regularly, as patient responses and appropriate dosage requirements often change over time.
[0004] The blood clotting system comprises a complex system of interconnected proenzymes, enzymes, and cofactors, each of which participates in the blood clotting process on the surface of activated platelets and endothelial cells, as well as in ruptured blood vessels. When the system is activated, such as at a vascular wound, the end result is the formation of a blood clot containing an insoluble fibrin network. In the human body, the clotting process is carefully regulated on the surface of activated platelets and endothelial cells. However, in laboratory settings, appropriate phospholipids are often used instead of the platelet surface. These proenzymes, enzymes, and cofactors are traditionally referred to as clotting factors (F).
[0005] The four clotting factors synthesized in the liver—FII, FVII, FIX, and FX—are inactive unless they undergo further carboxylation via a vitamin K-dependent enzymatic process after liver synthesis. In patients with vitamin K deficiency or those receiving vitamin K-dependent coagulation (VKA) therapy, the levels of carboxylated vitamin K-dependent (VKD) factors are reduced, leading to decreased blood clotting ability (i.e., coagulability). Unless the effects of VKA are controlled, this can result in serious and even fatal internal bleeding. However, by controlling the levels of VKD factors, abnormal intravascular clotting (thrombosis) can be avoided while minimizing the risk of bleeding. Therefore, the effects of VKA must be monitored through appropriate coagulation testing. Because patients' sensitivities to VKA effects vary, the dosage of VKA must also be individualized based on monitoring results. The dosage can be adjusted accordingly based on the test results to maximize antithrombotic effects while minimizing the risk of abnormal bleeding due to excessive anticoagulation.
[0006] In VKA patients, monitoring of coagulation activity has historically (for over seventy years) been based on the measurement of prothrombin time (PT), whether it was the original Quick PT (Quick, A., J Bio Chem 1935 (109): p. 73-4) or its modified version Owren's PT (also known as PP, P&P test or prothrombin complex assay) (Owren and Aas. Scand JClin Lab Invest, 1951. 3(3): p. 201-8). The Quick PT test measures the coagulation activity of three of the four vitamin K-dependent factors (i.e., FII, FVII, and FX) as well as fibrinogen (factor I) and factor V by adding coagulation reagents (thromboplastin, tissue factor) and calcium ions to a calcium-removed plasma sample and then measuring the time required for blood to clot. The latter test (P&P) is a modification of the Quick PT, in which adsorbed plasma (completely deficient in the four vitamin K-dependent factors: II, VII, IX, and X) is mixed into the test plasma, thus correcting for any possible deficiency of factor V or fibrinogen, making the P&P test sensitive only to factors II, VII, and X. Therefore, the Quick-PT test is also sensitive to deficiencies in factor V and fibrinogen, neither of which are vitamin K-dependent and could interfere with test results in patients taking VKA. However, for both tests, the measured clotting time is equally sensitive to reductions in any of the three vitamin K-dependent factors (FII, FVII, and FX) measured by either test. These tests cannot measure the clotting activity of FIX. In clinical practice, clotting time measured based on the Quick PT test is generally considered to directly reflect the antithrombotic effect of VKA in a patient's body, except in the initial stages of VKA treatment. However, this is not always the case.
[0007] Although routine warfarin monitoring using PT has the same sensitivity for reductions in any of FII, FVII, and FX (Gudmundsdottir BR et al, Thromb Res. 2012;130(4):674-81), experimental evidence, including that of the inventors of this disclosure, suggests that the antithrombotic effect of VKA drugs depends primarily on reductions in FII and FX, rather than reductions in FVII. (Gudmundsdottir BR et al, Thromb Res. 2012;130(4):674-81; Jonsson PI et al, J Thromb Haemost. 2017;15(1):131-9; Xi M et al, Thromb Haemost. 1989;62:788-91; Zivelin A et al, J Clin Invest. 1993;92:2131-40.) Furthermore, the rapid fluctuations in PT during VKA treatment are primarily driven by changes in FVII, which has an extremely short half-life. The extremely short half-life (4-6 hours) of FVII results in this specific factor having a significant impact on PT-INR in the short term (e.g., at the beginning of treatment, after dose changes, and during repeated dose changes in a short period before antithrombotic effects are observed).
[0008] Therefore, in considering whether to improve warfarin stability by monitoring only the effects of VKA on FII and FX, the inventors discovered a warfarin monitoring method called coagulation factor (F) II and X assay (Fiix assay, also known as Fiix prothrombin time or Fiix-PT). In the Fiix assay, the test plasma is corrected by mixing it with a plasma reagent from which factors II and X have been removed. This Fiix reagent method based on double-immunoremoved plasma is described in U.S. Patent No. 9,234,902 (“'902 Patent”). The plasma reagent corrects for deficiencies in all coagulation factors except factor II and factor X in the test plasma before adding a coagulation trigger (e.g., thrombin) to measure clotting time. The Fiix normalized ratio (Fiix-NR) is calculated in a similar manner to PT-INR, and by ignoring the reduction in FVII, a less volatile normalized ratio and a less volatile dose are obtained. (Jonsson PI et al, J Thromb Haemost.2017;15(1):131-9; Onundarson P et al, The Lancet Haematology. 2015;2(6):e231-e40; Oskarsdottir AR et al, Blood. 2021;137(20):2745-55.) In addition, in an investigator-initiated, blinded, mixed-population RCT, warfarin monitored by Fiix-NR (Fiix-warfarin) reduced the incidence of total thromboembolism (TE) by 48% without increasing bleeding compared with conventional PT-warfarin, and was statistically non-inferior. (Onundarson P et al, The Lancet Haematology. 2015;2(6):e231-e40.) Following the publication of these results, we replaced PT-INR monitoring with Fiix monitoring for warfarin in July 2016. Subsequently, we confirmed in a pre- and post-contrast interrupted time series study that the advantages of Fiix-warfarin over PT-warfarin were equally effective in clinical practice. (Oskarsdottir AR et al, Blood. 2021;137(20):2745-55.) The main drawbacks of existing methods, especially those using plasma reagents that are deficient in only factors II and X simultaneously (such as the Fiix reagent method described in the '902 patent), lie primarily in manufacturing costs and time. Specifically, the resources required to manufacture the Fiix deficient plasma reagent necessitate dual immunoremoval, i.e., chromatographically using two separately manufactured and expensive anti-factor II and anti-factor X antibodies on a chromatographic column. These antibodies bind to the relevant factors and remove them from the filtered plasma. The numerous steps involved in generating the deficient plasma reagent in existing methods necessitate a slow, methodical, and costly approach. Summary of the Invention
[0009] In view of the problems existing in the prior art, the inventors of this disclosure recognized the need for an improved detection method to monitor anticoagulation therapy. The inventors have developed a new method using a novel alternative reagent that provides factor VII but still lacks factors II and X. This alternative reagent can be used as a simplified deficiency plasma reagent or mixed into a trigger (e.g., thromboplastin) to provide reliable results while reducing manufacturing costs. An alternative solution of this disclosure provides a reagent plasma prepared using adsorbed (e.g., barium sulfate) plasma in which all vitamin K-dependent factors are removed, followed by the refilling of sufficient factor VII to correct the final concentration of FVII in the reagent-test whole blood or plasma sample mixture to more than 50% (0.5 u / mL). This reagent-test sample mixture still lacks FII, FX, and FIX. In this way, any effect of reduced FVII in the test blood or plasma sample on coagulation can be eliminated when the coagulation reaction is initiated using thromboplastin (tissue factor) and / or other reagents that directly activate coagulation factor X but not FIX. The proposed method bypasses the activation of coagulation factor IX and corrects for factor VII, thereby achieving the goal of measuring the simultaneous effects of FII and FX on the coagulation process only. Alternatively, reagent plasma and factor VII can be mixed with a reagent activator (e.g., thromboplastin) and then added to the patient's test plasma or whole blood to measure the same anticoagulant effect (i.e., measuring only the reduction of factors II and X). In other words, the method disclosed for monitoring anticoagulation therapy ignores or omits the effects of fibrinogen (FI), FV, and FVII on the coagulation process while measuring the simultaneous effects of FII and FX. Therefore, the method disclosed achieves reliable results at a lower manufacturing cost.
[0010] Therefore, this disclosure provides a method for determining the effect of an anticoagulant in a patient, based on measuring the effect of the anticoagulant on the combined activity of coagulation factors II and X only in a patient's plasma sample. The plasma sample is mixed with a plasma reagent lacking only factors II, IX, and X to prepare a corrected plasma sample. Subsequently, one or more coagulation reagents that activate factors VII or X, along with a calcium reagent, are added to the corrected plasma sample to initiate a blood coagulation procedure. The coagulation capacity of the corrected plasma sample is then determined by measuring clotting time or thrombin production. Alternatively, reagent plasma can be mixed with factor VII in a reagent activator (e.g., thrombin) and then added to the patient's plasma or whole blood to measure the same anticoagulant effect (i.e., measuring the reduction of factors II and X only).
[0011] This disclosure also relates to a method for monitoring anticoagulation therapy, the method comprising: (1) mixing adsorbed plasma with a solution containing factor VII to correct the final concentration of factor VII in the resulting sample mixture, the final concentration of factor VII being corrected to be greater than 50% or greater than 0.5 u / mL, the resulting sample mixture lacking factors II, X, and XI; (2) adding a coagulation reagent to the resulting sample mixture to initiate a coagulation reaction, wherein the coagulation reagent activates factor X directly or by forming a complex with activated factor VII (i.e., tissue factor, a component of thrombin) but does not activate factor IX; (3) determining the simultaneous effects of factors II and X on the coagulation reaction; and (4) determining the coagulation capacity of the resulting sample mixture by measuring clotting time or thrombin production. Based on the determined coagulation capacity, the dose of the anticoagulant can be adjusted to achieve a recommended therapeutic INR (international normalized ratio) of about 2 to about 3 (or other set targets), which is achieved by increasing the dose to maximize the antithrombotic effect of the anticoagulant or decreasing the dose to minimize the risk of abnormal bleeding due to excessive anticoagulation. As described above, the disclosed method may include the possibility of correcting for thromboplastin without employing a separate deficient plasma step. In other words, reagent plasma and factor VII may be mixed with a reagent activator (e.g., thromboplastin) and then added to the patient’s test plasma or whole blood to measure the same anticoagulant effect (i.e., to measure only the reduction of factors II and X).
[0012] This disclosure also provides a test kit for determining the activity of anticoagulants in a patient. The test kit includes a coagulation triggering reagent and factor-deficient plasma lacking vitamin K-dependent factors II, IX, and X. As described above, the factor-deficient plasma contains a sufficient amount of factor VII. In one embodiment, the factor-deficient plasma is prepared by adsorption, for example using barium sulfate or aluminum hydroxide, before reintroducing factor VII into the factor-deficient plasma; this is a standard procedure. The coagulation reagent is configured to directly activate factor VII or factor X, but not factor IX. Similar to the methods described above, the kit of this disclosure may also include means for directly correcting thromboplastin concentration without using separate deficient plasma. In one embodiment, purified FVII is mixed into thromboplastin premixed with adsorbed plasma before adding the modified thromboplastin to the test sample. The modified reagent comprises thromboplastin and bovine adsorbed plasma in a 1:1 ratio. By adding the reagent plasma and FVII to the test sample or the triggering reagent (e.g., thromboplastin), a coagulation time reflecting the combined (and only) activity of factors II and X can be obtained.
[0013] The methods and kits disclosed herein are designed to bypass FIX activation and correct for FVII (as well as FI (fibrinogen) and FV) to determine the synchronous effects of FIX and FX on the coagulation process.
[0014] These and other features, aspects and advantages of this disclosure will become more clearly understood in the following description and the appended claims.
[0015] definition "Coagulation reagent" refers to a reagent that can trigger the coagulation pathway in a blood or plasma sample, which causes prothrombin to be converted into thrombin and fibrinogen to be converted into fibrin.
[0016] The “combined activity” of factors II and X refers to the measured effect produced by the combined activity of factors II and X, but it is impossible to distinguish the effect of one factor from the effect of the other.
[0017] "Factor-deficient plasma" typically refers to normal plasma that has been treated to lack factors II, X, and IX, but in which sufficient amounts of factor VII have been reintroduced to correct the final concentration of factor VII in the resulting reagent-test whole blood or plasma sample mixture to more than 50% (0.5 u / mL).
[0018] "Normal plasma" refers to plasma suitable for use as a control, derived from normal healthy individuals, preferably and usually from a mixture of several individuals to normalize inter-individual differences in the concentration of relevant factors.
[0019] "Special coagulation triggering reagent" refers to a reagent (e.g., thromboplastin) premixed with adsorbed plasma (i.e., the source of all factors except factors II, VII, IX, and X), which has been supplemented or re-replenished with purified factor VII to ensure that the concentration of FVII in the final reagent-plasma or whole blood sample mixture exceeds 50% (0.5 u / mL).
[0020] In this article, “plasma to be tested,” “plasma sample to be tested,” or “blood to be tested” refers to plasma or whole blood from a patient or subject who requires blood coagulation testing.
[0021] "Viscosity" refers to a specific material property that determines the degree of gelation, such as the solidity or hardness of a material and its resistance to flowing like a fluid. Attached Figure Description
[0022] Figure 1 The expected normal ratio results obtained using different methods in FVII-deficient plasma are shown.
[0023] Figure 2 The effects of adding purified FVII thromboplastin on combined normal plasma and FVII-deficient plasma were demonstrated.
[0024] Figure 3 The effects of adding purified FVII thromboplastin on different deficient plasmas were demonstrated.
[0025] Figure 4 The effects of the PT-INR lacking in FVII and other alternative variants of this disclosure are shown. Detailed Implementation
[0026] This disclosure relates to a novel method and a corresponding kit based on this method for determining the coagulation capacity of a test sample (e.g., human plasma or whole blood), particularly suitable for determining the activity of anticoagulants in patients taking such medications. The disclosed method eliminates the influence of coagulation factors other than factors II and X. This method can improve the efficacy of coumarin (vitamin K antagonist, VKA) anticoagulation therapy, such as warfarin, which reduces the concentrations of activated (γ-carboxylated) coagulation factors II, VII, IX, and X. This novel method can also be applied to monitor other anticoagulants that inhibit factors II or X, or both. This method differs from standard prothrombin time (PT) assays, which are sensitive to reductions in vitamin K-dependent factor VII in addition to vitamin K-dependent factors II and X, and include two drug-independent factors, fibrinogen (FI) and factor V.
[0027] The method disclosed herein is based on the determination of the combined activity of coagulation factors II and X alone, which means that the effects of other factors that may be variable in the test sample (such as factors I, V and VII) are eliminated.
[0028] In one embodiment, the test sample is mixed with plasma lacking factors II, X, and IX (i.e., adsorbed plasma or factor-deficient plasma), wherein the factor-deficient plasma contains sufficient amount of factor VII to correct the final concentration of factor VII in the reagent-test whole blood or plasma sample mixture to more than 50% (0.5 u / mL). The ratio of test plasma to deficient plasma is suitably in the range of 1:1 to 1:20, preferably in the range of 1:2 to 1:5, including but not limited to 1:2.5, 1:3, 1:3.5, 1:4, or 1:4.5. As used herein, the symbol 1:2 indicates one part test plasma to two parts deficient plasma, i.e., a total of three plasmas (i.e., 33.3% test plasma and 66.7% deficient plasma). Alternatively, adsorbed plasma with added FVII is mixed with thromboplastin before adding the test sample to determine the same anticoagulant effect (i.e., to determine only the reduction of factors II and X).
[0029] In one embodiment, the plasma sample is processed in the same manner as a routine coagulation test: fresh blood samples collected from the patient are treated with citrate to remove calcium ions, and red blood cells are separated from the plasma by centrifugation. The prepared plasma sample can then be easily mixed with deficient plasma; this mixing can be performed either before analysis or in an automated instrument. In one embodiment, the plasma sample can be diluted with buffer or physiological saline. In another embodiment, the sample can be whole blood.
[0030] A coagulation reagent that activates coagulation factor VII or factor X but not factor IX is added to the plasma sample to be tested, along with a calcium reagent, to trigger coagulation. Calcium ions play a role in the activation of various coagulation factors, in addition to platelet activation. The coagulation reagent and calcium reagent can be pre-mixed together or added separately to the plasma sample. Alternatively, one or both reagents can be pre-mixed with the deficient plasma before adding calcium. Therefore, the method of this disclosure involves the steps of mixing the plasma sample to be tested with the deficient plasma and adding the coagulation reagent and calcium, which can be performed in one, two, or three steps. In one embodiment, the coagulation reagent is diluted with water, a saline solution, or a buffer solution. Those skilled in the art will recognize that a calcium reagent may not be necessary in test samples containing fresh whole blood. Therefore, in the proposed solution, the use and type of calcium reagent depend on the type of test sample (e.g., plasma sample versus fresh whole blood).
[0031] The coagulation reagent can be any reagent commonly used in routine testing, capable of activating coagulation factor X directly or by forming a complex with activating factor VIIa without activating factor IX. Examples of coagulation reagents used according to this disclosure include thromboplastin (including recombinant tissue factor), factor VIIa, and exogenous activators capable of activating factor X, such as snake venom.
[0032] This method works by activating coagulation through an exogenous pathway (high concentration of tissue factor activates FVII, which in turn activates factor X) or by directly activating factor X. In the methods disclosed herein, exogenous activators, such as snake venom, can be used. Such venoms include Russell's viper venom (from Daboia russellii), which can be obtained from natural sources or produced through recombinant synthesis. Other snake venoms that directly activate factor X via a common pathway can also be used in this invention.
[0033] Thromboplastin is not a pure protein, but a complex of tissue factor protein and phospholipids. Tissue factor (also known as platelet tissue factor, factor III, prothrombin kinase, or CD142) is an integrated transmembrane protein and a cell surface receptor for factor VI1a. It acts as an essential cofactor for the proteolytic activity of factor VI1a against factor X, converting factor X into the active protease factor Xa. According to one embodiment of this disclosure, the tissue factor binds to thrombophospholipids to fully exert its cofactor function.
[0034] The thromboplastin used in the methods and kits of this invention can be obtained from animal sources, including but not limited to rabbit brain, human placenta, human brain, bovine brain, bovine lung, or other suitable sources. The thromboplastin can also be recombinantly produced, preferably recombinant human thromboplastin. Recombinant thromboplastin can be produced by expressing tissue factor components in suitable cell cultures, such as mouse placental cell cultures, hamster ovary cells (CHO cells); fungal cells, prokaryotes, such as E. coli cultures; transgenic plants, or other suitable expression vectors, followed by in vitro lipidation of the tissue factor.
[0035] The calcium reagent is typically, but not necessarily, derived from calcium chloride. The amount / concentration of the coagulation reagent used in this method is generally similar to that currently used in methods for determining coagulation. The calcium concentration is conventional, for example, 1.0–4.0 mM, preferably 2.5 mM.
[0036] When using thrombin, the results can be normalized based on the ISI value to obtain a normalized ratio.
[0037] Coagulation reagents and / or deficient plasma are preferably lyophilized, in which case they should be reconstituted with water or a suitable buffer solution before use.
[0038] Based on the disclosed method for determining the effect of anticoagulants in a patient, the recommended therapeutic INR of about 2 to about 3 (or other target range) can be achieved by adjusting the dose of the anticoagulant, which can be done by increasing the dose to maximize the antithrombotic effect of the anticoagulant or decreasing the dose to minimize the risk of abnormal bleeding due to excessive anticoagulation.
[0039] In one embodiment, a method for determining the simultaneous effects of anticoagulants on coagulation factors II and X only includes the step of mixing the test plasma with a source of coagulation factor VII to prevent the influence of factor VII on the test results. The source of factor VII may be a plasma reagent lacking only factors II, IX, and X but not factor VII, to prepare a corrected mixed plasma sample; or it may be achieved by adding an excess of coagulation factor VII to the test sample or trigger.
[0040] In one implementation, a whole blood or plasma sample from a patient receiving anticoagulation therapy with a vitamin K antagonist is mixed with a solution containing purified factor VII at a concentration sufficient to give the final activity of the mixture greater than 50% (>0.5 u / mL). The entire common coagulation pathway is measured, namely factors I (fibrinogen), II, V, and X, but excluding VII. For samples from patients taking vitamin K antagonists such as warfarin, the combined effects of FII and X should be monitored because fibrinogen and factor V are unaffected by vitamin K antagonist effects and therefore remain stable in fresh samples from patients treated with vitamin K antagonists. This method is preferably used when there is no deficiency in fibrinogen and / or factor V levels.
[0041] End point determination The endpoint determination methods disclosed herein include, but are not limited to: manual (visual) determination by tilting tube technique; mechanical determination using clot detection methods such as "rolling ball" or vibrating probe technique (detecting the moment when the probe comes to rest due to increased viscosity); optical detection methods using optical detection of fibrin formation; and colorimetric techniques based on chromogenic substrates, including thrombin substrates (e.g., substrate S2238 (Chromogenix-Instrumentation Laboratory SpA, Milano, Italy)) and FXa substrates, such as BIOPHEN CS-11 (22) (Aniara, Mason Ohio, USA). Other manual and / or visual methods for coagulation detection may also be employed.
[0042] Other embodiments include the use of fluorescent substrates that release a fluorescent label upon cleavage by an amidolytic enzyme (e.g., thrombin or factor Xa). These embodiments include, but are not limited to, peptide-4-methylcoumaramide (MCA), such as Pefafluor Fxa (Pefa-5534) (Pentapharm Ltd., Basel, Switzerland), a sensitive substrate for factor Xa. In other embodiments, luminescent substrates are used, including substrate S-2613 (tert-butoxycarbonyl-isoleucyl-glutamyl-γ-piperidinyl-glycyl-arginyl-isoluminol); for other substrates, see, for example, Hemker HC, Handbook of synthetic substrates for the coagulation and fibrinolytic system, Martinus Nijhoff Publishers, Boston (1983).
[0043] In one embodiment, the method further includes the step of adjusting the dose of the anticoagulant to achieve a pre-set target recommended therapeutic INR, which can be achieved by increasing the dose to maximize the antithrombotic effect of the anticoagulant or by reducing the dose to minimize the risk of abnormal bleeding due to excessive anticoagulation.
[0044] The reagent kit disclosed herein In another aspect, this disclosure provides one or more kits suitable for monitoring anticoagulation therapy in a variety of clinical laboratory and point-of-care testing. Therefore, these kits are formulated to provide the reagents required for testing according to the methods of this disclosure in appropriate quantities and ready-to-use containers. The test kit includes, for example, coagulation reagents (such as one or more mentioned above in the description of the methods of this disclosure) contained separately in individual containers, and normal plasma lacking only factors II, IX, and X (i.e., factor-deficient plasma), or coagulation reagents mixed with factor-deficient plasma in a single container, or a solution containing purified factor VII at a concentration sufficient to give the final activity of the mixture greater than 50% (>0.5 u / mL).
[0045] Factor-deficient plasma refers to plasma lacking only factors II, X, and IX, and therefore still contains other coagulation factors, including factor VII. This factor-deficient plasma is suitably prepared according to the method described above, i.e., normal plasma is adsorbed, for example using barium sulfate or other suitable adsorbents to remove factors II, VII, IX, and X, and then factor VII is added back to the adsorbed plasma at a sufficient concentration so that the activity of factor VII in the final mixture of the test sample and the deficient plasma exceeds 50%. In one embodiment, the factor-deficient plasma is artificially prepared and produced by an immunoremoval method. In other words, the kit includes a coagulation reagent and factor-deficient plasma lacking vitamin K-dependent factors II, IX, and X, wherein the factor-deficient plasma contains sufficient amount of factor VII so that the final concentration of factor VII in the reaction mixture reaches at least 0.50 u / mL (50% activity or 0.25 µg / mL).
[0046] In some embodiments, the kit of this disclosure also includes a calcium ion source, which may be placed separately in a designated container or provided together with coagulation reagents or deficient plasma. In other embodiments, calcium is not provided as part of the kit because many laboratories and coagulation devices already have suitable sources of calcium reagents. For example, in point-of-care testing, when the sample to be tested is whole blood, such as fresh, unanticoagulated blood, no calcium needs to be added.
[0047] In some embodiments, particularly those related to point-of-care testing, the coagulation reagent and deficient plasma, or purified factor VII, may be placed in a single container or located on the surface of a reagent strip or well, which may or may not contain calcium ions. In other embodiments, the coagulation reagent and deficient plasma are placed in separate containers.
[0048] Coagulation reagents and deficient plasma are preferably provided in lyophilized powder form, whether these substances are provided separately or combined in the same vial. One or more containers should be suitably configured so that the lyophilized material can be reconstituted in the original container.
[0049] The following examples are intended to further illustrate to those skilled in the art how to prepare and use the contents of this disclosure. However, these examples are not intended to limit the scope of this disclosure.
[0050] Example 1 In general, this disclosure provides a solution for monitoring anticoagulation therapy using reagent plasma made from plasma to which all vitamin K-dependent factors have been removed, followed by the reintroduction of a solution containing sufficient factor VII to correct the final concentration of factor VII in the reagent-test whole blood or plasma sample mixture. The resulting sample mixture still lacks only factors II, X, and IX, thus eliminating the effect of reduced factor VII on coagulation when a coagulation reagent (e.g., thromboplastin or other reagent that directly activates factor X but not factor IX) is used to initiate the coagulation reaction. Example 1 describes a solution for bypassing factor IX activation and correcting for factor IX to determine the simultaneous effects of factors II and X on the coagulation process.
[0051] This disclosure relates to a method in which a plasma sample to be tested is mixed with plasma lacking (i.e., completely depleted) factors II, X, and IX to correct for any possible deficiency of other coagulation factors in the sample. The coagulation time is then measured after activation of coagulation using a coagulation reagent that can directly activate coagulation factor X or activate coagulation factor X by forming a complex with factor VIIa (i.e., thromboplastin / tissue factor). Thus, the subsequent test results reflect only the activity of coagulation factors II and X.
[0052] This assay can be performed manually, by semi-automatic, or by automated coagulation analyzers. Compared to existing methods sensitive to reductions in factors II, VII, and X when measuring prothrombin time (PT), the method disclosed herein is sensitive only to reductions in factors II and X, providing optimal results. PT is sensitive to reductions in factor VII as well as factors II and X in the test sample. Due to its short half-life, factor VII fluctuates, and these fluctuations are not synchronized with those of factors II and X; when factors II or X are normal, factor VII may be very low. Such fluctuations can affect test results and dosage management when using conventional PT methods; however, the method and kit disclosed herein bypass factor IX activation, correct for any influence of factor VII, and accurately measure only the synchronized effects of factors II and X on the coagulation process—the effects of these two coagulation factors that lead to the antithrombotic effect of vitamin K antagonists.
[0053] The test results can be obtained and recorded as clotting time, clotting time ratio, or other calculated values. The experimental results shown in this example are based on the determination of clotting time, for example, using thromboplastin and a modified reagent (i.e., a thromboplastin / adsorbed plasma mixture) as the clotting reagent. The obtained purified factor VII is then added to it.
[0054] The plasma sample to be tested (patient plasma) is mixed with factor-deficient plasma. This factor-deficient plasma is normal plasma that has undergone adsorption treatment, for example, by removing factors II, VII, IX, and X using barium sulfate or other suitable adsorbents, followed by the addition of a sufficient concentration of factor VII so that the factor VII activity in the final mixture of the test sample and the deficient plasma exceeds 50%. Using this mixture, the test reaction is initiated by adding thrombin and calcium, allowing for the measurement of clotting time sensitive only to reductions in factors II and X. Depending on the resulting clotting time, the ratio of test plasma to factor-deficient plasma can range from 1:1 to 1:20, preferably from 1:2 to 1:5 (see below). Alternatively, factor-deficient plasma can be mixed with purified factor VII in thrombin, or purified factor VII can be mixed with a thrombin / adsorbed plasma mixture.
[0055] In the experimental results of Example 1, the method involved mixing 10 μL of test plasma with 25 μL of factor-deficient plasma. This factor-deficient plasma contained at least 0.8 μL / mL of factor VII and was deficient in factors II, IX, and X. The ratio of test plasma to factor-deficient plasma was 1:2.5, resulting in a final concentration of FVII in the mixture >0.5 μL / mL. Subsequently, before adding thrombin and calcium, 70 μL of Owren's buffer (e.g., composed of sodium diethylbarbiturate, sodium chloride, hydrochloric acid, and distilled water) at a pH of approximately 7.33 was added to bring the total volume to 105 μL, thereby determining the clotting time.
[0056] The obtained results can be used to reliably and specifically determine reduced concentrations of factors II and X without interference from factor VII exceeding 0.5 u / mL in the mixture. For accurate determination of factor II and X concentrations as low as <2 u / dL, the preferred ratio of test plasma to factor-deficient plasma should be in the range of 1:2 to 1:10.
[0057] Example 2 Example 2 describes a comparison of mixing the blood or plasma to be tested with the method of this disclosure (using adsorbed plasma with added FVII) prior to the addition of thromboplastin, as in a prior detection method, wherein the prior detection method is described in U.S. Patent No. 9,234,902 (“902 Patent”), wherein plasma lacking only Factor II and Factor X after double immunization is used, filed March 7, 2012, and published January 12, 2016 by Fiix Diagnostics.
[0058] The plasma reagent disclosed in the aforementioned US patent includes a method for removing plasma using a dual immunoassay (FII) and FX method before the addition of thrombolytic enzyme and calcium chloride. In this prior detection method, the aim is to determine the simultaneous effects of reduced FII and FX only during warfarin monitoring. This is achieved by mixing the FII and FX dual immunoassay-removed plasma with a citrate-treated plasma sample before the addition of thrombolytic enzyme and calcium chloride. In this way, deficiencies in all factors other than FII and FX in the test plasma are corrected, so that clotting time reflects only the reduction in FII and FX. However, the dual immunoassay of the plasma reagent has proven to be a time-consuming and costly preparation method.
[0059] The method disclosed herein achieves the goal of simultaneously measuring only the reduced effects of FII and / or FX by replacing the double-immunoassay plasma with plasma adsorbed with barium sulfate (or by other methods) and supplemented with an excess of FVII but still lacking FII, FX, and FIX. The concentration of FVII added is preferably such that the factor activity in the mixture of test plasma and reagent plasma exceeds 50%. FIX is also still lacking in the reagent plasma; however, since thrombin can activate FVII and bypass FIX, the measurement of FIX is not important. Therefore, the assay is only affected by the reduction of FII and / or FX.
[0060] Figure 1 The effect of adding FVII to the test plasma before adding thrombin is demonstrated. Normalized ratios were calculated using different thrombin reagents for plasma samples with progressively increasing FVII concentrations (from 0.0–0.7 µg / ml = 0–140% FVII activity). The average normal FVII concentration is approximately 0.5 µg / ml = 100% activity. Figure 1 This indicates that although PT-INR is affected by low factor VII levels, other detection methods successfully eliminated the effect of low FVII activity.
[0061] The reagents used include: a control test without the addition of FVII to the test plasma (PT INR); test plasma with the addition of purified FVII (in the final test sample containing the reagent mixture, the FVII activity is 94%; i.e., the FVII activity is not less than 94%); a disclosed method (adsorbed plasma with added FVII, wherein FVII is mixed into the test plasma (final activity >65%), and thrombin is added separately); and a prior art detection method (mixing FII and FX-deficient plasma with approximately 100% FVII activity with the test plasma (final activity >50%), and adding thrombin separately).
[0062] The results showed that only the standard control assay was affected by FVII concentrations below approximately 0.4 microg / ml (<80%). All other plasma reagent methods were able to correct for any degree of FVII deficiency in the test sample and were therefore unaffected by the FVII activity of the test sample, thus suitable for the simultaneous detection of factor II and X activities. Example 2 supports the conclusion that the solution disclosed herein introduces a faster and more cost-effective method that is readily industrially viable while achieving results similar to (i.e., bioequivalent) to prior detection methods.
[0063] Example 3 Example 3 supports an alternative implementation of the disclosed method and describes the role of adding purified FVII to the thromboplastin (rather than to the plasma to be tested). Figure 2 The effect of thromboplastin with added purified factor VII on concomitant normal plasma and FVII-deficient plasma was demonstrated. Thromboplastin or thromboplastin with added purified factor VII (pFVII) was added to concomitant normal plasma (PNP, approximately 100% FVII) and FVII-deficient plasma (0% FVII). Two concentrations of pFVII were added to the thromboplastin to obtain a final FVII activity of not less than 93-186% in the plasma-thromboplastin mixture to be tested.
[0064] Figure 2 The results show that when FVII-deficient plasma was originally in a normal state, the addition of thromboplastin containing purified FVII corrected the clotting time. In other words, the thromboplastin mixed with purified FVII (ensuring that the FVII activity in the final mixture was at least 93%) successfully eliminated the effect of low FVII concentration in the test plasma on clotting time.
[0065] Figure 3 This study demonstrated the effect of adding purified FVII-laced thromboplastin on different plasma types. The experiment determined the effects of control thromboplastin (i.e., conventional thromboplastin) and thromboplastin supplemented with purified FVII on clotting time in combined normal plasma, Fiix-deficient adsorbed plasma supplemented with 65% FVII, and immune-removed plasma (including FII-deficient, FX-deficient, FVII-deficient, and FV-deficient plasma).
[0066] like Figure 3 The results further demonstrate that adding purified FVII to thromboplastin to achieve a final activity of at least 93% has little or no effect on clotting time in concomitant normal plasma, FII- and FX-deficient plasma, or FV-deficient plasma. However, adding purified FVII to thromboplastin can correct clotting time in FVII-deficient plasma to normal levels, thus clotting time is no longer affected by the concentration of FVII in the test plasma.
[0067] Example 4 Example 4 describes the following sensitivities: PT Owren's test sample thromboplastin mixed with adsorbed plasma (diluted and undiluted test samples); regular PT Quick thromboplastin; Fiix adsorbed plasma with added purified FVII; Fiix thromboplastin mixed with adsorbed plasma (diluted and undiluted samples) with added purified FVII; and Fiix thromboplastin with added purified FVII (i.e., Fiix common pathway assay). In this assay, Quick PT contains thromboplastin. Fiix PT using reagents with added FVII includes thromboplastin containing excess purified FVII, referred to as the "common pathway assay," which is sensitive to reductions in FI, FII, FV, and FX. Owren's PT includes the thromboplastin reagent Simplastin A (i.e., SPA thromboplastin), which mixes adsorbed plasma and thromboplastin as a source of fibrinogen and factor V; this type of assay involves using both undiluted plasma and plasma diluted 1:7 with Owren's buffer. The Fiix PT using reagents containing purified FVII comprises excess purified FVII, undiluted plasma, and plasma diluted at a 1:7 ratio with a buffer solution consisting of sodium diethylbarbiturate, sodium chloride, hydrochloric acid, and distilled water (i.e., FII-FX detection with added thromboplastin from the adsorbed plasma). The disclosed method also includes adsorbed plasma with added FVII plasma reagent, wherein the thromboplastin is added separately.
[0068] Figure 4 The coagulation times in combined normal plasma (100% = 1.0 u / ml) and plasma with 3% FVII activity (0.03 u / ml) are shown. As can be seen, all Fiix assays (including prior assays and the methods of this disclosure) successfully eliminated the effect of FVII on coagulation time, i.e., the coagulation times of PNP and 3% FVII-deficient plasma were similar.
[0069] The Fiix-NR (normalized ratio) method of this disclosure, in undiluted Fiix test samples, uses a modified reagent (i.e., a mixture of thromboplastin / adsorbed plasma) with added purified FVII (pFVII), and the results show no difference in clotting time. Example 4 shows that this assay can be performed on whole blood and can be applied to point-of-care testing. Therefore, this disclosure can further be considered for a detection method using a pFVII assay with added modified reagent (i.e., containing thromboplastin and bovine adsorbed plasma in a 1:1 ratio), which can be used for point-of-care testing based on whole blood.
[0070] In another embodiment, the disclosed method and / or kit includes adsorbed plasma with added purified FVII, and mixing the adsorbed plasma with the test blood or plasma before adding thrombin and calcium chloride. The solution contains one part (25 µL) of the test plasma and one part (25 µL) of a modified buffer (e.g., Owren-Koller buffer) with added purified FVII to achieve a concentration of 0.7 µg / ml. In this two-part mixture, the added pFVII is 0.35 µg / ml fc (=70% activity). In other words, the FVII activity in the test plasma dilution will exceed 70%. Other formulations may include FVII activity as low as 50%. After preparing the two-part mixture, four parts (100 µL) of thrombin (e.g., Quick type) and calcium chloride are added, followed by measurement of clotting time. Other formulations may include FVII activity as low as 50% and different volumes of buffer with added pFVII.
[0071] In another embodiment, the disclosed method and / or kit includes a modified (thromboplastin-based) reagent containing purified FVII, wherein the modified reagent comprises thromboplastin and bovine adsorbed plasma in a 1:1 ratio. The modified reagent containing purified FVII and calcium chloride is first added to the blood or plasma to be tested. This solution contains one part (50 µL) of undiluted plasma and two parts (100 µL) of the modified reagent containing 0.7 µg / ml fc (140% activity) of purified FVII. The FVII activity in this mixture is 93%. Other formulations may use purified FVII as low as 0.4 µg / ml fc (80% activity) in the spiking buffer to obtain a final activity exceeding 50% in the plasma-thromboplastin mixture. In one embodiment, the modified reagent is a mixture of thromboplastin and barium sulfate adsorbed plasma, used as a correction source for all coagulation factors in the plasma to be tested, except for vitamin K-dependent factors (II, VII, IX, and X). By adding purified FVII to the reagent and triggering coagulation with thromboplastin, the assay is sensitive only to reductions in FII and FX.
[0072] It should be understood that not all objectives or advantages can be achieved under any of the embodiments disclosed herein. Those skilled in the art will recognize that the proposed methods and kits for monitoring anticoagulation therapy can be embodied or performed to achieve or optimize one or more of the advantages taught herein without achieving other objectives or advantages taught or suggested herein.
[0073] Those skilled in the art will recognize that the various features disclosed are interchangeable. In addition to the variations described herein, those skilled in the art can combine and match other known equivalents of each feature in accordance with the principles of this disclosure to construct and use alternative plasma reagents. Those skilled in the art will understand that the features described herein are adaptable to other methods and other types of diagnostic devices / applications.
[0074] This disclosure should not be limited to the embodiments and examples disclosed above, and can be extended to other applications that may employ the features described herein.
Claims
1. A method for determining the effect of an anticoagulant in a patient, said effect being based on determining the effect of the anticoagulant on the combined activity of coagulation factors II and X alone in a test sample from said patient, said method comprising: Plasma reagents lacking only factors II, IX, and X were mixed into the test sample to prepare a calibrated test sample; Add one or more coagulation reagents that can activate factor VII or factor X but not factor IX; as well as The coagulation capacity of the calibrated test sample is determined by measuring clotting time or thrombin production.
2. The method according to claim 1, further comprising the following step: The purified factor VII-replenished adsorbed factor II, VII, IX and X deficient plasma is added to the test sample, or to one or more coagulation reagents including thromboplastin, to correct the deficiency of factor VII in the test sample or the corrected test sample, as well as the deficiency of other factors besides factors II, IX and X.
3. The method according to claim 1, wherein the sample to be tested is plasma, and the method further comprises the following steps: Calcium is added to the calibrated test sample.
4. The method according to claim 1, wherein the sample to be tested is unanticoagulated whole blood.
5. The method according to claim 1, further comprising the following step: The dosage of anticoagulants is adjusted to achieve a pre-set target recommended therapeutic INR, which is achieved by increasing the dosage to maximize the antithrombotic effect of the anticoagulant or by decreasing the dosage to minimize the risk of abnormal bleeding due to excessive anticoagulation.
6. The method of claim 1, wherein the plasma reagent contains at least 0.8 u / mL (0.4 µg / mL) of factor VII.
7. The method of claim 1, wherein one or more coagulation reagents are selected from the group consisting of: i) Thromboplastin; ii) Exogenous activators, including snake venom that can activate factor X; and iii) Factor VIIa.
8. The method according to claim 1, wherein the anticoagulant is an oral anticoagulant.
9. The method of claim 1, further comprising the step of diluting the sample with a buffer solution or physiological saline.
10. The method according to claim 1, wherein the one or more coagulation reagents are diluted with water, a saline solution or a buffer solution.
11. The method of claim 1, wherein at least one component of the coagulation reagent, plasma reagent, or calcium source is lyophilized, and wherein the method further comprises the step of reconstituted the at least one component.
12. A test kit for determining the activity of anticoagulant drugs in a patient, the test kit comprising: Coagulation reagents, and Deficiency of vitamin K-dependent factors II, IX, and X in plasma; The factor-deficient plasma contains at least 0.8-1.0 u / mL (0.5 µg / mL) of factor VII.
13. The test kit of claim 12, comprising a coagulation reagent and a plasma lacking a specific antigen in a container.
14. The test kit of claim 12, wherein the coagulation reagent is configured to directly activate factor X and not activate factor IX.
15. The test kit according to claim 12, further comprising: The first container for holding clotting reagents; as well as A second container for factor-deficient plasma.
16. The detection kit according to claim 12, wherein, The factor-deficient plasma contains purified factor VII provided at a sufficient concentration such that the final activity of the combined mixture of the coagulation reagent, the factor-deficient plasma, and the test sample from the patient exceeds 50% or is greater than 0.5 u / mL.
17. The test kit according to claim 12, wherein the coagulation reagent is selected from one or more of the following: i) Thromboplastin; ii) Exogenous activators, including snake venom that can activate factor X; and iii) Factor VIIa.
18. The detection kit according to claim 17, wherein the factor-deficient plasma is adsorbed with barium sulfate or aluminum hydroxide.
19. A method for monitoring anticoagulation therapy, the method comprising: The adsorbed plasma was mixed with a solution containing factor VII to correct the final concentration of factor VII in the resulting sample mixture. The adsorbed plasma was deficient in vitamin K-dependent factors II, VII, X, and IX, and the final concentration of factor VII was corrected to be greater than 50% or greater than 0.5 u / mL. The resulting sample mixture was deficient only in factors II, X, and IX. A coagulation reagent is added to the resulting sample mixture to initiate a coagulation reaction, wherein the coagulation reagent directly activates factor X but does not activate factor IX; The simultaneous effects of measuring factors II and X on the coagulation response; and The coagulation capacity of the obtained sample mixture is determined by measuring clotting time or thrombin production.
20. A method for determining the effect of an anticoagulant in a patient, said effect being based on determining the effect of the anticoagulant in a test sample from the patient on the combined activity of coagulation factors II and X alone, said method comprising: The plasma reagent lacking only factors II, IX, and X is mixed with one or more coagulation reagents that can activate factor VII or factor X but not factor IX. The mixed plasma reagent and one or more coagulation reagents are added to the test sample to prepare the calibrated test sample. The coagulation capacity of the calibrated test sample is determined by measuring clotting time or thrombin production.
Citation Information
Patent Citations
Method for monitoring anticoagulant therapy
US9234902B2
